Vera Therapeutics Overview

  • Founded
  • 2011

Founded

  • Status
  • Public

  • Employees
  • 49

Employees

  • Stock Symbol
  • VERA

Stock Symbol

  • Investments
  • 2

  • Share Price
  • $14.52
  • (As of Friday Closing)

Vera Therapeutics General Information

Description

Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.

Contact Information

Website
www.veratx.com
Formerly Known As
CDF Therapeutics, Trucode Gene Repair
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Drug Delivery
Stock Exchange
NAS
Primary Office
  • 170 Harbor Way
  • 3rd Floor
  • South San Francisco, CA 94080
  • United States
+1 (650) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Vera Therapeutics Stock Performance

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$14.52 $14.90 $5.20 - $23.39 44.3M 560K -$3.33

Vera Therapeutics Financials Summary

In Thousands,
USD
TTM 30-Jun-2023 FY 2022 31-Dec-2022 FY 2021 31-Dec-2021 FY 2020 31-Dec-2020
EV 543,920 434,811 482,347
Revenue 0 0 0 0
EBITDA (110,136) (89,813) (32,427) (53,003)
Net Income (107,349) (89,056) (32,609) (53,413)
Total Assets 195,178 131,435 83,748 54,554
Total Debt 30,093 31,286 4,923 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Vera Therapeutics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Vera Therapeutics‘s full profile, request access.

Request a free trial

Vera Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Vera Therapeutics‘s full profile, request access.

Request a free trial

Vera Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transfo
Drug Discovery
South San Francisco, CA
49 As of 2023
00000
00000000 00000

000000

incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostr
0000000000000
Grand Cayman, Cayman Islands
00 As of 0000
000
000000000 - 000

000000

mpor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis
0000 000000000
Middleton, WI
00 As of 0000
000.00
0000000000 0 000.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Vera Therapeutics Competitors (64)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Polaris Group (California) Formerly PE-Backed Grand Cayman, Cayman Islands 00 000 000000000 - 000
00000000 Venture Capital-Backed Middleton, WI 00 000.00 0000000000 0 000.00
000000000 Formerly VC-backed Gaithersburg, MD 00 00000 00000000 00000
00000 000000000 Formerly VC-backed South San Francisco, CA 000 00000 000000 - 000 00000
00000000 000000000 Formerly VC-backed San Diego, CA 000 00000 0000000000.
You’re viewing 5 of 64 competitors. Get the full list »

Vera Therapeutics Patents

Vera Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2021288699-A1 Dosing of polyomavirus neutralizing antibodies Pending 12-Jun-2020 0000000000
CA-3186736-A1 Dosing of polyomavirus neutralizing antibodies Pending 12-Jun-2020 0000000000
EP-4165078-A1 Dosing of polyomavirus neutralizing antibodies Pending 12-Jun-2020 0000000000
US-20230220051-A1 Dosing of polyomavirus neutralizing antibodies Pending 12-Jun-2020 0000000000
US-11681862-B1 System and method for identifying location of content within an electronic document Active 22-Apr-2019 G06F40/117 00
To view Vera Therapeutics’s complete patent history, request access »

Vera Therapeutics Executive Team (9)

Name Title Board Seat Contact Info
Marshall Fordyce MD Chief Executive Officer & Board Member
Sean Grant Chief Financial Officer, Finance
Joanne Curley Ph.D Chief Development Officer
Celia Lin MD Chief Medical Officer
You’re viewing 4 of 9 executive team members. Get the full list »

Vera Therapeutics Board Members (10)

Name Representing Role Since
Andrew Cheng Ph.D Self Board Member 000 0000
Beth Seidenberg MD Self Board Member 000 0000
Krishna Yeshwant MD Self Board Member 000 0000
Maha Katabi Ph.D Sofinnova Investments Board Member 000 0000
Marshall Fordyce MD Vera Therapeutics Chief Executive Officer & Board Member 000 0000
You’re viewing 5 of 10 board members. Get the full list »

Vera Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Vera Therapeutics Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Vera Therapeutics‘s full profile, request access.

Request a free trial

Vera Therapeutics Investments & Acquisitions (2)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
000000 000000 17-Dec-2021 000000000 0000 Buildings and Property 00000000
PNA Innovations 26-Apr-2021 Merger/Acquisition 00.000 Biotechnology
To view Vera Therapeutics’s complete investments and acquisitions history, request access »

Vera Therapeutics ESG

Risk Overview

Risk Rating

Updated April, 01, 2022

34.19 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

00.0

Management

Management is related to actions taken to manage ESG issues

00.00

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

00 of 15,491

Rank

00.00

Percentile

Pharmaceuticals

Industry

00 of 871

Rank

00.00

Percentile

Biotechnology

Subindustry

00 of 389

Rank

00.0

Percentile

To view Vera Therapeutics’s complete esg history, request access »